TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16618403
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks of peginterferon-alfa-2a (180 microg/wk) plus ribavirin (800 mg/day)
Study: 16618403
Drug: 72 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 72 weeks of peginterferon-alfa-2a (180 microg/wk) plus ribavirin (800 mg/day)
Study: 16618403
Drug: 72 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 72 weeks of treatment for patients HCV-RNA positive at week 12
Study: 14563580
Drug: Activated protein
Normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated protein C (APC) at 0.06 mg/kg per day
Study: 14563580
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin at 100 to 400 U/kg per day
Study: 11459333
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg/day titrated to a maximum of 20 mg/day)
Study: 9205772
Drug: Cordaflex 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordaflex 20 mg retard filmtablet
Study: 3677542
Drug: Lamotrigine 120
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 120 mg
Study: 16476149
Drug: T allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: T allele of G protein beta3 (GNbeta3)
Study: 9197351
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment group (15 mg/kg/day)
Study: 31160805
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve block combined with subcutaneous perineal anaesthesia and intrarectal lidocaine gel
Study: 28062082
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (Control group, n=30)
Study: 26604652
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patient controlled intravenous analgesia)
Study: 21600087
Drug: Antofloxacin hydrochloride
Normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antofloxacin hydrochloride tablet
Study: 21600087
Drug: Levofloxacin tablet
Normalized name: Levofloxacin Tablets
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin tablet
Study: 12868802
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 every 3 weeks for four cycles
Study: 10470596
Drug: Amtolmetin guacyl
Normalized name: Amtolmetin guacil
DrugBank: Amtolmetin guacil (DB16088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetin guacyl 600 mg bid
Study: 7041522
Drug: 1,25(OH)2D3 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 (0.5 micrograms daily)
Study: 19660001
Drug: Branded amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Branded amoxicillin
Study: 17551492
Drug: Post-treatment groups
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment groups (adjuvant therapy)
Study: 11472320
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with ranitidine (300 mg), amoxicillin (1000 mg), and clarithromycin (500 mg) for 7 days
Study: 9493257
Drug: Anti-hypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive treatment A
Study: 9493257
Drug: Anti-hypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive treatment B
Study: 7931701
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.65 mg)
Study: 7931701
Drug: Vitamin B‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B‐12 (0.4 mg)
Study: 7931701
Drug: Vitamin B‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B‐6 (10 mg)
Study: 7931701
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of folic acid, vitamin B‐12, and vitamin B‐6
Study: 3348136
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) oral spray
Study: 21280077
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (20 mg and 40 mg)
Study: 19878986
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice daily as tolerated)
Study: 16861405
Drug: RA plus
Normalized name: Mokura Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA plus clonidine 1 microg/kg as the initial loading dose followed by 1 microg.kg(‐1).h(‐1)
Study: 12611558
Drug: Oral fenugreek
Normalized name: FENUGREEK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenugreek seed powder
Study: 28968167
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg plus cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Study: 28968167
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Study: 28968167
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus chemotherapy in T790M mutation-positive patients
Study: 28968167
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus chemotherapy in T790M mutation-negative patients
Study: 28968167
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy in T790M mutation-negative patients
Study: 23408495
Drug: Intravenous carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous carbamazepine (CBZ) 100 mg dose as partial replacement of morning dose
Study: 23408495
Drug: Intravenous carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous carbamazepine (CBZ) 100 mg dose
Study: 19394661
Drug: glyburide 10
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: glyburide 10 mg/d
Study: 15658652
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng injection (SFI) plus conventional therapy (mainly glucocorticoids)
Study: 15658652
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (mainly glucocorticoids)
Study: 30623096
Drug: bococizumab 150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: bococizumab 150, 300, or 450 mg co‐mixed with rHuPH20
Study: 30623096
Drug: bococizumab 300
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bococizumab 300 mg + rHuPH20
Study: 30623096
Drug: bococizumab 300
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bococizumab 300 mg alone
Study: 20463587
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (clear liquid diet, 4 L of PEG, and 1 or 2 NaP boosters)
Study: 20463587
Drug: Modified regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified regimen (1 or 2 PEG boosters, 4 senna tablets, and a low-residue diet)
Study: 19356075
Drug: Cyclosporine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (single oral dose)
Study: 19356075
Drug: Cyclosporine PBMC
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine PBMC pharmacokinetics
Study: 12552363
Drug: Hydrocodone bitartrate
Normalized name: Hydrocodone Bitartrate
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hydrocodone bitartrate (7.5 mg) plus ibuprofen (200 mg)
Study: 9365149
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg by mouth twice a day for eight weeks
Study: 31037562
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily for 8 weeks
Study: 31037562
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg daily for 8 weeks
Study: 21896132
Drug: 10% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycolic acid containing oil-in-water emulsion applied once daily in the evening for 90 days
Study: 19219442
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of a steroid (1 mL triamcinolone) combined with local anaesthetic (1 mL lidocaine) in group A
Study: 19219442
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anaesthetic (1 mL lidocaine) combined with peppering technique in group B
Study: 19219442
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of a steroid (1 mL triamcinolone) combined with local anaesthetic (1 mL lidocaine) and peppering technique in group C
Study: 14523786
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered recombinant interleukin-2 (rIL-2)
Study: 14523786
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy without rIL-2 (Control)
Study: 9890319
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with glycopeptide (vancomycin or teicoplanin) and ceftazidime
Study: 9890319
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with glycopeptide (vancomycin or teicoplanin) and ceftazidime
Study: 9890319
Drug: Intermittent ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent ceftazidime treatment
Study: 9890319
Drug: Continuous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous ceftazidime treatment
Study: 9890319
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with glycopeptide and ceftazidime
Study: 9890319
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with glycopeptide and ceftazidime
Study: 9890319
Drug: Intermittent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent and continuous treatment
Study: 7752906
Drug: Gemfibrozil 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 1,200 mg daily for 12 weeks
Study: 21858548
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg elemental Zn per day)
Study: 18269665
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied to one side of the operation area for 7 days
Study: 1626795
Drug: Nasal administration
Normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal administration of beclamethasone dipropionate (400 micrograms total, 100 micrograms four times per day)
Study: 1626795
Drug: Bronchial administration
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial administration of beclamethasone dipropionate (400 micrograms total, 100 micrograms four times per day)
Study: 1626795
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered into the nose when B was administered into the bronchi and vice versa)
Study: 29697876
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg/d)
Study: 29697876
Drug: Platinum-based therapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based therapy plus pemetrexed (500 mg/m2)
Study: 29697876
Drug: Platinum-based therapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based therapy plus pemetrexed
Study: 27492510
Drug: Ang‐2 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ang‐2 levels in survivors during treatment
Study: 20577923
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) for 10 days perioperation (7 days preoperatively and 3 days postoperatively)
Study: 20577923
Drug: Non total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non total parenteral nutrition (NTPN)
Study: 3593896
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate controlled release (600 mg day-1 for 4 days)
Study: 3593896
Drug: Quinidine gluconate
Normalized name: Quinidine Gluconate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine gluconate controlled release (600 mg day-1 for 4 days)
Study: 3593896
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate extended-release (300 mg q12h)
Study: 3593896
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate in solution (150 mg q6h)
Study: 3593896
Drug: Quinidine gluconate
Normalized name: Quinidine Gluconate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine gluconate controlled-release (q12h)
Study: 27443598
Drug: Sarcosine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcosine (0.03 g/kg/day)
Study: 25585502
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine 0.25% + 1 μg/kg Dex (GIII)
Study: 19038771
Drug: Pregabalin, 300
Normalized name: Pregabalin, 300 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin, 300 mg single oral dose
Study: 19038771
Drug: Morphine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine, 10 mg IV
Study: 19038771
Drug: Diphenhydramine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine, 50 mg oral dose
Study: 16803605
Drug: 7-day ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day ranitidine bismuth citrate-based triple therapy (ranitidine bismuth citrate + amoxicillin + clarithromycin)
Study: 16803605
Drug: 4-day ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day ranitidine bismuth citrate-based triple therapy (ranitidine bismuth citrate + amoxicillin + clarithromycin)
Study: 12784408
Drug: Standard non-physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard non-physiotherapy treatment (control group).
Study: 30057908
Drug: Intradermal microdroplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal microdroplet injection
Study: 30057908
Drug: Intradermal microdroplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal microdroplet group
Study: 30057908
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Intramuscular injection)
Study: 11941946
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bd and Amoxicillin 1 g bd (LA)
Study: 11941946
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bd and Amoxicillin 1 g bd (OA)
Study: 11941946
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bd, Amoxicillin 1 g bd and Clarithromycin 500 mg bd (LAC)
Study: 9921806
Drug: Daclizumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1.0 mg/kg every other week for five doses)
Study: 7573900
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol anaesthesia (IVA)
Study: 2304255
Drug: GOE anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOE anesthesia and 0.2 mg epidural Bn every three hours (group B)
Study: 2304255
Drug: GOE anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOE anesthesia and 0.2 mg epidural Bn every six hours (group C)
Study: 6994765
Drug: Guanfacine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 1.0 mg intravenously
Study: 6670282
Drug: Chloroquine diphosphate
Normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine diphosphate (25 mg and 50 mg)
Study: 6670282
Drug: Chloroquine diphosphate
Normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine diphosphate (above 100 mg)
Study: 30620668
Drug: pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 200 mg every 3 weeks for up to 2 years
Study: 30620668
Drug: platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: platinum-based chemotherapy (four to six cycles)
Study: 30620668
Drug: pembrolizumab (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab (after crossover from chemotherapy)
Study: 27289488
Drug: Fixed low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose of low-molecular-weight heparin (LMWH)
Study: 27289488
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose of low-molecular-weight heparin (LMWH)
Study: 24131674
Drug: EU paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EU paricalcitol dosing regimen (initial μg dose based on iPTH/80)
Study: 24131674
Drug: US paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: US paricalcitol dosing regimen (initial dose of 0.04 μg/kg)
Study: 22492669
Drug: Short message
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short message service maintenance treatment (SMSMT) for 9 months
Study: 22492669
Drug: Short message
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short message service maintenance treatment (SMSMT)
Study: 18478278
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg intramuscularly (arm A)
Study: 18478278
Drug: Ondansetron 16
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 16 mg orally (arm B)
Study: 15955118
Drug: Nicotine 0
Normalized name: nicotine 0.35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 0 mg + Caffeine 0 mg
Study: 15955118
Drug: Nicotine 1
Normalized name: nicotine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 1 mg + Caffeine 50 mg
Study: 15955118
Drug: Nicotine 1
Normalized name: nicotine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 1 mg + Caffeine 100 mg
Study: 15955118
Drug: Nicotine 2
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 2 mg + Caffeine 50 mg
Study: 15955118
Drug: Nicotine 2
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 2 mg + Caffeine 100 mg
Study: 12061413
Drug: Classroom cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom cognitive‐behavioral treatment (CBT)
Study: 12061413
Drug: Home‐based audio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home‐based audio relaxation treatment (HART)
Study: 12061413
Drug: Delayed‐treatment control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed‐treatment control
Study: 7668036
Drug: Adsorbed DT
Normalized name: L-DT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adsorbed DT vaccine (n = 51)
Study: 7668036
Drug: Fluid DT
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid DT vaccine (n = 53)
Study: 2206782
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dipyridamole
Study: 2206782
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg acetylsalicylic acid
Study: 7192617
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (subjected to 'conflict' 2 h daily for 12 weeks)
Study: 28166324
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with a systolic BP target of less than 120 mm Hg (n = 1317)
Study: 28166324
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with a BP target of less than 140 mm Hg (n = 1319)
Study: 23612453
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg per day until progression or unacceptable toxicity
Study: 21942502
Drug: Post-therapy communication
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-therapy communication changes
Study: 21942502
Drug: Post-therapy levels
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-therapy levels of problem solving and changes in wives' positivity
Study: 14578410
Drug: Lomerizine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomerizine 0.1 mg/kg